

Position Statement on prescribing Eflornithine 11.5% (Vaniqa®) cream

Following the Barking and Dagenham, Havering and Redbridge Clinical Commissioning Groups (BHR CCGs) Area Prescribing sub-Committee (APC) meeting held on Tuesday 26th June 2018, the BHR CCGs agree to stop prescribing of Eflornithine 11.5% (Vaniqa®) cream.

**From Tuesday 17th April 2018,
Barking and Dagenham, Havering and Redbridge Clinical Commissioning
Groups (BHR CCGs) no longer supports the prescribing of
Eflornithine 11.5% (Vaniqa®) cream**

Decision

- The decision to stop the prescribing of Eflornithine 11.5% (Vaniqa®) cream applies to **ALL** patients across Barking and Dagenham, Havering and Redbridge.
- BHR CCGs have agreed **NO** exceptions to this recommendation
- Prescribers are **not** to undertake any new requests to prescribe Eflornithine 11.5% (Vaniqa®) cream on the NHS
- Prescribers should review and de-prescribe Eflornithine 11.5% (Vaniqa®) cream prescribed to their patients

This decision was made because:

- Eflornithine 11.5% cream (Vaniqa®) offers very little benefit for the management of facial hirsutism. There is limited evidence for efficacy and patient satisfaction with Eflornithine 11.5% cream (Vaniqa®)
- BHR CCGs recommend patients to self-fund cosmetic treatments for reduction in hair growth or hair removal (e.g. shaving, plucking, depilatory cream, laser treatment, and electrolysis) as the primary options for patients with hirsutism
- BHR CCGs have a duty to spend taxpayer's money wisely, to make sure they get the best value possible – especially when NHS funding is being severely squeezed and more patients are being seen with more complex health issues than ever before